The National Institutes of Health and Bill Gates have announced that the two former head of the Gates Foundation will jointly oversee a vaccine trial that will run for one year, beginning in 2019.
Gates and Mcfadden will each be responsible for coordinating the vaccine trials, which will take place in several countries.
Gates said in a statement that the trial will be a pivotal first step in creating a global vaccine delivery network.
“We are very excited about the potential for this vaccine to be delivered in the United States and the world, and look forward to working closely with the National Institutes to make sure this trial is as robust and robust as possible,” he said.
The announcement comes after a long-delayed trial involving the vaccine developed by Gates and his former colleagues at the Broad Institute in Cambridge, Massachusetts.
The trial has been a source of much frustration to some in Congress and the public, as Gates has made it clear that he would rather be testing a vaccine that is already in use than trying something new.
The Gates vaccine will use a “humanizing” compound, the company said, as opposed to the more traditional “anti-viral” ones that are currently used in vaccines.
Gates has said that he wants to be able to say, “I’ve tested it and it works.”
In a statement, Gates called the trial “a unique opportunity to explore a potential vaccine for the disease of pandemic flu,” but added that he expects it will take at least two years to complete.
The NIH has been working with Mcfadem in Cambridge to develop the vaccine.
The vaccine is a combination of three strains of a coronavirus and a virus that infects the lungs, according to the NIH.
In the United Kingdom, the government is expected to give the vaccine to children under the age of five in a trial that begins next month.
The first dose of the vaccine is expected by the end of next year.
(Reuters) The announcement came a day after the CDC announced that it will be extending a two-year trial for the vaccine, the first of its kind to be conducted by the federal government.
The agency also announced that its new vaccine testing protocol will allow for testing of a vaccine at the federal level, which means that the public will be able use the vaccine at a public health facility.
This is important, because the CDC will be providing vaccine samples for the next phase of the trial, which is set to begin in 2019, and this phase will be the most challenging, as the vaccine itself is highly antigenic.
The CDC said that testing will also be conducted in the Netherlands and India.
The government is not expected to start administering the vaccine until 2021.
The NIH and Broad Institute said in their joint statement that they have developed the vaccine in collaboration with the US Centers for Disease Control and Prevention and the National Institute of Allergy and Infectious Diseases, and that they will jointly conduct vaccine testing in 2018.
The Broad Institute is one of the world’s leading vaccine development companies.
The company said in its statement that its vaccine will be used to fight off influenza, which has killed more than 3 million people in the US and Canada since 2014.
The vaccines have been used in at least seven countries, including Australia, Canada, Germany, Mexico, New Zealand, the United Arab Emirates, the UK, and the United Nations.
(Reuters) In addition to the vaccine testing, the NIH is also working with a team of scientists to help run a series of clinical trials to determine whether the vaccine can prevent and even reverse severe respiratory infections.
The trials are expected to begin later this year.
The initial phase of trials will involve the vaccine being administered to people in clinical trials in the U.S. and other countries.
The final phase of clinical testing will begin in 2021 and will include more than 1,000 people who will receive doses of the flu vaccine.
(Reuters / Bloomberg)